Full Text:   <610>

Summary:  <221>

Suppl. Mater.: 

CLC number: 

On-line Access: 2023-08-08

Received: 2022-10-13

Revision Accepted: 2023-03-10

Crosschecked: 2023-08-08

Cited: 0

Clicked: 770

Citations:  Bibtex RefMan EndNote GB/T7714


Jin LI


Huijie ZHANG


-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2023 Vol.24 No.8 P.682-697


Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway

Author(s):  Shenjian LUO, Zhi YANG, Ruxin CHEN, Danming YOU, Fei TENG, Youwen YUAN, Wenhui LIU, Jin LI, Huijie ZHANG

Affiliation(s):  Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; more

Corresponding email(s):   jinli807@126.com, huijiezhang2005@126.com

Key Words:  Cytokine receptor-like factor 1 (CRLF1), TGF‍, -‍, β, 1/SMAD signaling pathway, ERK1/2 signaling pathway, Cardiac fibrosis, Myofibroblast transformation, Extracellular matrix (ECM)

Shenjian LUO, Zhi YANG, Ruxin CHEN, Danming YOU, Fei TENG, Youwen YUAN, Wenhui LIU, Jin LI, Huijie ZHANG. Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway[J]. Journal of Zhejiang University Science B, 2023, 24(8): 682-697.

@article{title="Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway",
author="Shenjian LUO, Zhi YANG, Ruxin CHEN, Danming YOU, Fei TENG, Youwen YUAN, Wenhui LIU, Jin LI, Huijie ZHANG",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway
%A Shenjian LUO
%A Ruxin CHEN
%A Danming YOU
%A Youwen YUAN
%A Wenhui LIU
%A Jin LI
%A Huijie ZHANG
%J Journal of Zhejiang University SCIENCE B
%V 24
%N 8
%P 682-697
%@ 1673-1581
%D 2023
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200506

T1 - Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway
A1 - Shenjian LUO
A1 - Zhi YANG
A1 - Ruxin CHEN
A1 - Danming YOU
A1 - Fei TENG
A1 - Youwen YUAN
A1 - Wenhui LIU
A1 - Jin LI
A1 - Huijie ZHANG
J0 - Journal of Zhejiang University Science B
VL - 24
IS - 8
SP - 682
EP - 697
%@ 1673-1581
Y1 - 2023
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200506

cardiac fibrosis is a cause of morbidity and mortality in people with heart disease. Anti-fibrosis treatment is a significant therapy for heart disease, but there is still no thorough understanding of fibrotic mechanisms. This study was carried out to ascertain the functions of cytokine receptor-like factor 1 (CRLF1) in cardiac fibrosis and clarify its regulatory mechanisms. We found that CRLF1 was expressed predominantly in cardiac fibroblasts. Its expression was up-regulated not only in a mouse heart fibrotic model induced by myocardial infarction, but also in mouse and human cardiac fibroblasts provoked by transforming growth factor-‍;β;1 (TGF‍;-‍;β;1). Gain- and loss-of-function experiments of CRLF1 were carried out in neonatal mice cardiac fibroblasts (NMCFs) with or without TGF-‍;β;1 stimulation. CRLF1 overexpression increased cell viability, collagen production, cell proliferation capacity, and myofibroblast transformation of NMCFs with or without TGF‍;-‍;β;1 stimulation, while silencing of CRLF1 had the opposite effects. An inhibitor of the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway and different inhibitors of TGF-‍;β;1 signaling cascades, comprising mothers against decapentaplegic homolog (SMAD)‍-dependent and SMAD-independent pathways, were applied to investigate the mechanisms involved. CRLF1 exerted its functions by activating the ERK1/2 signaling pathway. Furthermore, the SMAD-dependent pathway, not the SMAD-independent pathway, was responsible for CRLF1 up-regulation in NMCFs treated with TGF-‍;β;1. In summary, activation of the TGF-‍;β;1/SMAD signaling pathway in cardiac fibrosis increased CRLF1 expression. CRLF1 then aggravated cardiac fibrosis by activating the ERK1/2 signaling pathway. CRLF1 could become a novel potential target for intervention and remedy of cardiac fibrosis.




Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1]BacmeisterL, SchwarzlM, WarnkeS, et al., 2019. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol, 114(3):19.

[2]BarronL, WynnTA, 2011. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol, 300(5):G723-728.

[3]BasheyRI, Martinez-HernandezA, JimenezSA, 1992. Isolation, characterization, and localization of cardiac collagen type VI. Associations with other extracellular matrix components. Circ Res, 70(5):1006-1017.

[4]BerkBC, FujiwaraK, LehouxS, 2007. ECM remodeling in hypertensive heart disease. J Clin Invest, 117(3):568-575.

[5]BiernackaA, CavaleraM, WangJH, et al., 2015. Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circ Heart Fail, 8(4):788-798.

[6]BrownRD, AmblerSK, MitchellMD, et al., 2005. The CARDIAC FIBROBLAST: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol, 45:657-687.

[7]BuersI, PersicoI, SchöningL, et al., 2020. Crisponi/cold-induced sweating syndrome: differential diagnosis, pathogenesis and treatment concepts. Clin Genet, 97(1):209-221.

[8]BuschA, ŽarkovićM, LoweC, et al., 2017. Mutations in CRLF1 cause familial achalasia. Clin Genet, 92(1):‍104-108.

[9]ChaffinM, PapangeliI, SimonsonB, et al., 2022. Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy. Nature, 608(7921):174-180.

[10]ChildersRC, SunyeczI, WestTA, et al., 2019. Role of the cytoskeleton in the development of a hypofibrotic cardiac fibroblast phenotype in volume overload heart failure. Am J Physiol Heart Circ Physiol, 316(3):H596-H608.

[11]ChouCH, HungCS, LiaoCW, et al., 2018. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res, 114(5):690-702.

[12]DerynckR, ZhangYE, 2003. Smad-dependent and Smad-independent pathways in TGF-‍β family signalling. Nature, 425(6958):577-584.

[13]DewaldO, RenGF, DuerrGD, et al., 2004. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol, 164(2):665-677.

[14]DisertoriM, MasèM, RavelliF, 2017. Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med, 27(5):363-372.

[15]Fernández-AlfonsoMS, RuilopeLM, 2014. One step forward for serelaxin as a promising therapy in cardiac fibrosis. Hypertension, 64(2):229-230.

[16]FrangogiannisNG, 2017. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest, 127(5):1600-1612.

[17]FrangogiannisNG, 2019. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med, 65:70-99.

[18]FrangogiannisNG, 2020. Transforming growth factor-‍β in tissue fibrosis. J Exp Med, 217(3):e20190103.

[19]GuptaS, GeY, SinghA, et al., 2021. Multimodality imaging assessment of myocardial fibrosis. JACC Cardiovasc Imaging, 14(12):2457-2469.

[20]HannaA, FrangogiannisNG, 2019. The role of the TGF‍-‍β superfamily in myocardial infarction. Front Cardiovasc Med, 6:140.

[21]HerholzJ, MeloniA, MarongiuM, et al., 2011. Differential secretion of the mutated protein is a major component affecting phenotypic severity in CRLF1-associated disorders. Eur J Hum Genet, 19(5):525-533.

[22]HorbeltD, DenkisA, KnausP, 2012. A portrait of transforming growth factor β superfamily signalling: background matters. Int J Biochem Cell Biol, 44(3):469-474.

[23]HuHH, ChenDQ, WangYN, et al., 2018. New insights into TGF‍-‍β/Smad signaling in tissue fibrosis. Chem Biol Interact, 292:76-83.

[24]JanickiJS, BrowerGL, 2002. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail, 8(6):S319-S325.

[25]JugduttBI, 2003. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation, 108(11):1395-1403.

[26]KoenigAL, ShchukinaI, AmruteJ, et al., 2022. Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure. Nat Cardiovasc Res, 1(3):263-280.

[27]KongP, ChristiaP, FrangogiannisNG, 2014. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci, 71(4):549-574.

[28]LattanzioFAJr, TiangcoD, OsgoodC, et al., 2005. Cocaine increases intracellular calcium and reactive oxygen species, depolarizes mitochondria, and activates genes associated with heart failure and remodeling. Cardiovasc Toxicol, 5(4):377-389.

[29]LeiH, WuD, WangJY, et al., 2015. C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation. Basic Res Cardiol, 110(4):35.

[30]LiRK, LiGM, MickleDAG, et al., 1997. Overexpression of transforming growth factor-‍β1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation, 96(3):‍874-881.

[31]LiYF, XunJ, WangBT, et al., 2021. miR-3065-3p promotes stemness and metastasis by targeting CRLF1 in colorectal cancer. J Transl Med, 19:429.

[32]LodygaM, HinzB, 2020. TGF‍-‍β1—a truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol, 101:123-139.

[33]LooyengaBD, ResauJ, MacKeiganJP, 2013. Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. PLoS ONE, 8(6):e66548.

[34]LópezB, RavassaS, MorenoMU, et al., 2021. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol, 18(7):479-498.

[35]MagayeRR, SaviraF, HuaY, et al., 2020. Exogenous dihydrosphingosine 1 phosphate mediates collagen synthesis in cardiac fibroblasts through JAK/STAT signalling and regulation of TIMP1. Cell Signal, 72:109629.

[36]MagayeRR, SaviraF, HuaY, et al., 2021a. Attenuating PI3K/Akt-mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells. Int J Biochem Cell Biol, 134:105952.

[37]MagayeRR, SaviraF, XiongX, et al., 2021b. Dihydrosphingosine driven enrichment of sphingolipids attenuates TGFβ induced collagen synthesis in cardiac fibroblasts. IJC Heart Vasc, 35:100837.

[38]MantovaniA, SicaA, LocatiM, 2005. Macrophage polarization comes of age. Immunity, 23(4):344-346.

[39]MengJX, QinYY, ChenJZ, et al., 2020. Treatment of hypertensive heart disease by targeting Smad3 signaling in mice. Mol Ther Methods Clin Dev, 18:791-802.

[40]MengXM, Nikolic-PatersonDJ, LanHY, 2016. TGF‍-‍β: the master regulator of fibrosis. Nat Rev Nephrol, 12(6):325-338.

[41]NagarajuCK, RobinsonEL, AbdesselemM, et al., 2019. Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure. J Am Coll Cardiol, 73(18):2267-2282.

[42]NguyenMN, KiriazisH, GaoXM, et al., 2017. Cardiac fibrosis and arrhythmogenesis. Compr Physiol, 7(3):1009-1049.

[43]NguyenTP, QuZL, WeissJN, 2014. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol, 70:83-91.

[44]PerestreloAR, SilvaAC, Oliver-De La CruzJ, et al., 2021. Multiscale analysis of extracellular matrix remodeling in the failing heart. Circ Res, 128(1):24-38.

[45]RoubilleF, BusseuilD, MerletN, et al., 2014. Investigational drugs targeting cardiac fibrosis. Expert Rev Cardiovasc Ther, 12(1):111-125.

[46]ScaliseRFM, de SarroR, CaraccioloA, et al., 2021. Fibrosis after myocardial infarction: an overview on cellular processes, molecular pathways, clinical evaluation and prognostic value. Med Sci (Basel), 9(1):16.

[47]SchmiererB, HillCS, 2007. TGFβ‍-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol, 8(12):970-982.

[48]SchuetzeKB, McKinseyTA, LongCS, 2014. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. J Mol Cell Cardiol, 70:100-107.

[49]ShenY, TengYS, LvYP, et al., 2020. PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer. J Immunother Cancer, 8(2):e000422.

[50]ShirwanyA, WeberKT, 2006. Extracellular matrix remodeling in hypertensive heart disease. J Am Coll Cardiol, 48(1):97-98.

[51]SinghR, KaundalRK, ZhaoBY, et al., 2021. Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling. Pharmacol Res, 167:105414.

[52]StefanovicL, StefanovicB, 2012. Role of cytokine receptor-like factor 1 in hepatic stellate cells and fibrosis. World J Hepatol, 4(12):356-364.

[53]StrattonMS, BagchiRA, FelisbinoMB, et al., 2019. Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation. Circ Res, 125(7):662-677.

[54]SundararajK, PleasantDL, MoschellaPC, et al., 2016. mTOR complexes repress hypertrophic agonist-stimulated expression of connective tissue growth factor in adult cardiac muscle cells. J Cardiovasc Pharmacol, 67(2):110-120.

[55]The Tabula Muris Consortium, CoordinationOverall, CoordinationLogistical, et al., 2018. Single-cell transcriptomics of 20 mouse organs creates a Tabula muris. Nature, 562(7727):367-372.

[56]TuYG, WuTQ, DaiAZ, et al., 2011. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-‍β in diabetic nephropathy. Kidney Int, 79(2):199-209.

[57]TuckerNR, ChaffinM, FlemingSJ, et al., 2020. Transcriptional and cellular diversity of the human heart. Circulation, 142(5):466-482.

[58]TuletaI, FrangogiannisNG, 2021. Fibrosis of the diabetic heart: clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev, 176:113904.

[59]UmbarkarP, EjantkarS, TousifS, et al., 2021. Mechanisms of fibroblast activation and myocardial fibrosis: lessons learned from FB-specific conditional mouse models. Cells, 10(9):2412.

[60]WangJC, ZhaoHK, ZhengL, et al., 2021. FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells. Theranostics, 11(10):5045-5060.

[61]WangXW, MaJP, ZhangSS, et al., 2021. G protein-coupled estrogen receptor 30 reduces transverse aortic constriction-induced myocardial fibrosis in aged female mice by inhibiting the ERK1/2-MMP-9 signaling pathway. Front Pharmacol, 12:731609.

[62]WangZY, ShenJK, SunW, et al., 2019. Antitumor activity of raddeanin A is mediated by jun amino-terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma. Cancer Sci, 110(5):1746-1759.

[63]WeberKT, 1989. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol, 13(7):1637-1652.

[64]WenJX, LiMJ, ZhangWW, et al., 2022. Role of higenamine in heart diseases: a mini-review. Front Pharmacol, 12:798495.

[65]WestermannD, van LinthoutS, DhayatS, et al., 2007. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol, 102(6):500-507.

[66]WynnTA, 2008. Cellular and molecular mechanisms of fibrosis. J Pathol, 214(2):199-210.

[67]XiaY, DobaczewskiM, Gonzalez-QuesadaC, et al., 2011. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension, 58(5):‍902-911.

[68]YamaguchiO, WatanabeT, NishidaK, et al., 2004. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest, 114(7):937-943.

[69]YuP, MaSC, DaiXC, et al., 2020. Elabela alleviates myocardial ischemia reperfusion-induced apoptosis, fibrosis and mitochondrial dysfunction through PI3K/AKT signaling. Am J Transl Res, 12(8):4467-4477.

[70]YuST, ZhongQ, ChenRH, et al., 2018. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways. Cell Death Dis, 9(3):371.

[71]YuST, SunBH, GeJN, et al., 2020. CRLF1-MYH9 interaction regulates proliferation and metastasis of papillary thyroid carcinoma through the ERK/ETV4 axis. Front Endocrinol (Lausanne), 11:535.

[72]ZhaoK, ZhangJ, XuTH, et al., 2021. Low‐intensity pulsed ultrasound ameliorates angiotensin II-induced cardiac fibrosis by alleviating inflammation via a caveolin-1-dependent pathway. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(10):818-838.

[73]ZhengZY, AoX, LiP, et al., 2020. CRLF1 is a key regulator in the ligamentum flavum hypertrophy. Front Cell Dev Biol, 8:858.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE